Medical Advocates
Nelfinavir (Viracept)
 
Archived Conference Citations


4th International Workshop on Clinical Pharm of HIV
 2nd IAS Conference
1st European HIV Drug Resistance Workshop
 9th CROI
 XIV International AIDS Conference
41st ICAAC
3rd International Workshop on Clinical Pharm of HIV




 
Nelfinavir Main Page Conferences Main Page Home Page
Last Update:  September 07, 2007
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader .
Perinatal  data are integrated with Perinatal Conference Data in the Perinatal Data Page.   Pediatric data are integrated with
Pediatric Conference Data in the Pediatric Data Page
4th International Workshop on Clinical Pharmacology
of HIV Therapy
2nd IAS Conference on HIV and Pathogenesis
       
  • THE EFFECT OF EFAVIRENZ (EFV) AND NELFINAVIR (NFV) ON THE PHARMACOKINETICS
    PK) OF PRAVASTATIN (P)
    JG Gerber, S Rosenkranz, CJ Fichtenbaum    , et al,
    Abstract
  • THE EFFECT OF ILLICIT DRUG USE, METHADONE MAINTENANCE PROGRAM AND PAST
    ILLICIT DRUG USE ON TREATMENT OUTCOME IN A LARGE COHORT OF PATIENTS
    TREATED WITH NELFINAVIR
    H Knobel, J Collazos, JL Casado,         et al
    Abstract
  • POPULATION PHARMACOKINETICS OF INDINAVIR AND NELFINAVIR/M8 IN HIV-PATIENTS
    TREATED WITH A STABLE ANTIRETROVIRAL THERAPY
     K. Brendel, X. Panhard, M. Legrand, et al
     Abstract
    •
  • POPULATION PHARMACOKINETICS OF INDINAVIR AND NELFINAVIR/M8 IN HIV-PATIENTS
    TREATED WITH A STABLE ANTIRETROVIRAL THERAPY
     F Mentré, K Brendel, X. Panhard, et al
     Abstract
  • POPULATION PHARMACOKINETICS OF NELFINAVIR (NFV) ADMINISTERED BID OR TID AND
    PHARMACOKINETIC PREDICTORS OF HIV SUPPRESSION
    PH. Hsyu, EV Capprelli, J Lane,         et al
     Abstract
  • ROCHE VIRACEPT (NELFINAVIR) 625 MG FILM-COATED TABLETS: INVESTIGATION OF
    SAFETY AND GASTROINTESTINAL TOLERABILITY OF THIS NEW FORMULATION IN
    COMPARISON WITH 250 MG FILM-COATED TABLETS (VIRACEPTâ) IN HIV PATIENTS
    M. Johnson, L. Nieto-Cisneros, A. Horban,      et al
     Abstract
  • IMPACT OF NELFINAVIR (NFV) AND ITS ACTIVE METABOLITE M8 TROUGH LEVELS (TL) ON
    VIROLOGIC RESPONSE FROM PRIMARY HIV-1 VERTICALLY INFECTED CHILDREN TREATED
    WITH STAVUDINE (D4T), DIDANOSINE (DDI) AND NFV IN THE PENTA 7 STUDY
    A. Compagnucci, Y. Saïdi, A. Faye,          et al
     Abstract
  • LIPID PROFILE ALTERATIONS INDUCED BY THREE DIFFERENT PI-CONTAINING REGIMENS
    (NELFINAVIR, LOPINAVIR/RITONAVIR AND INDINAVIR/RITONAVIR) IN A COHORT OF HIV-
    INFECTED PATIENTS
    V. Joly, J. Gerbe, F. Driss,          et al
     Abstract
  • IMPACT OF NELFINAVIR (NFV) AND ITS ACTIVE METABOLITE M8 TROUGH LEVELS (TL) ON
    VIROLOGIC RESPONSE FROM PRIMARY HIV-1 VERTICALLY INFECTED CHILDREN TREATED
    WITH STAVUDINE (D4T), DIDANOSINE (DDI) AND NFV IN THE PENTA 7 STUDY
    Compagnucci, Y. Saïdi, A. Faye,      et al
     Abstract
  • STEP-WISE INTERVENTION FOR THE MANAGEMENT OF NELFINAVIR (NFV)-ASSOCIATED
    DIARRHEA
    A. Rachlis, M.J. Gill, J.G. Baril,          et al
     Abstract
  • TRANSVERSAL STUDY TO CORRELATE PLASMA NELFINAVIR CONCENTRATION,
    ANTIRETROVIRAL THERAPY COMPLIANCE, AND GENOTYPE RESISTANCE/DIFFERENCES
    IN HIV POSITIVE PATIENTS IN STABLE TREATMENT
    A. Cassinello, S. García, P. Guerra,          et al
     Abstract
1st European HIV Drug Resistance Workshop
 
9th Conference on Retroviruses and Opportunistic
Infections        
  • CONFERENCE PDF POSTER
     Nelfinavir Unbound Drug Interactions and Protein Binding Characteristics
    F. Aweeka, T. Motoya, L. Thevanayagam, et al.
    PDF Poster     Abstract
  • Pharmacokinetics, Antiviral Activity, and Safety of Nelfinavir (NFV) with ZDV/3TC in Pregnant
    HIV-Infected Women and Their Infants: PACTG 353 Cohort 2
    Abstract
  • Evidence of Systemic P-Glycoprotein (P-gp) Inhibitory Activity in Patients Receiving Twice-Daily
    Nelfinavir (Viracept)      
     Abstract
  • Different Pathways to Nelfinavir Genotypic Resistance in HIV-1 Subtypes B and G
    Abstract
    •
XIV International AIDS Conference
 
  • Impact of low dose ritonavir (rtv) on pharmacokinetics (PK) of nelfinavir (NFV) and its active metabolite
    M8 in HIV infected patients
    F Raffi, L Nieto, M Hernandez-Jacome, et al
    Abstract
  • Nelfinavir versus Indinavir/ritonavir in treatment naive patients : comparison of efficacy and safety
    at one year
     S De Wit, R Boulmé, D Konopnicki, et al
    Abstract
  • Indinavir and nelfinavir pharmacokinetics in patients with sustained virological response on HAART,
    the cophar I – ANRS 102 study
    C Goujard, M Legrand, F Mentre, et al
     Abstract
  • Prolonged successful therapy with Nelfinavir in inner city women
    P Greiger-Zanlungo, P Alpert, C Smith, G Blick
     Abstract
  • Efficacy and durability of nelfinavir after initial virologic failure of an NNRTI regimen
    C Cohen, M Royal, D Melton,  et al
     Abstract
  • Management of nelfinavir-related diarrhoea
    E Negredo, G Sirera, J Puig, et al
     Abstract
  • Cerebrospinal fluid (CSF) HIV-RNA supressed by Saquinavir and Nelfinavir in combination with 2
    Nucleoside Analogues
    M Gisslen, L Hagberg, B Svennerholm,
     Abstract
  • Retrospective analysis of nelfinavir containing antiretroviral combinations in treatment experienced
    patients
    E Weiss, J S Cervia, P Dali, K Freeman
     Abstract
  • Gastric Bypass Surgery and Serum Concentrations of Zidovudine, Lamivudine, and Nelfinavir
    RR Razonable, L Estes, M McMahon,
     Abstract
  • Tolerability of nelfinavir for HAART
    MA Horberg, D B Klein, T T Luu, K Sinn
     Abstract
  • Durability of nelfinavir based HAART
    By MA Horberg, D B Klein, et al
     Abstract
  • Is L90M mutation selected more frequently in non-B subtype HIV1 infected patients failing
    on Nelfinavir-containing HAART?
    L Navaratne, W Tong, I Christie, 
     Abstract
  • Comparison of virologic response in a cohort of women and men treated with Nelfinavir
    containing HAART regimens
    P Keiser, N N Nassar, G Koen, S Moreno
     Abstract
    •
  • A comparison of the pharmacokinetics of nelfinavir in African-American women versus men
    with HIV infection
    R Sharma, B Bellantone, D Singh, et al
         Abstract
  • The impact of prior nucleoside reverse transcriptase inhibitor experience on nelfinavir durability
    FJ Palella, J Gathe, A Brutus,     et al
     Abstract
  • Nelfinavir (NFV) resistance mutations during a follow-up period of 108 weeks in PI-naive patients
    treated with NFV-containing regimens in an HIV clinic cohort
    S Oka, K Tsuchiya, S Ida    , et al
     Abstract
  • Combined regimen of dietary supplementation and exercise reduces diarrhea, increases
    muscular strength,and improves quality of life (QOL) in HIV+ men receiving Nelfinavir (NFV)
    CR Heiser, N French, MM Russert, R Slotten,    et al
     Abstract
    •
  • Nelfinavir (NFV), but not its major M8 metabolite, inhibits systemic P-glycoprotein (P-gp) activity
    during HIV therapy
    JP Donahue, D Dowdy, KK Ratnam, et al
    Abstract
  • A randomised trial comparing HAART regimens of Nelfinavir/Nevirapine (N/N) and Ritonavir/
    Saquinavir (R/S) in PI and NNRTI naive patients
    O Kirk, JD Lundgren, C Pedersen,     et al
     Abstract
  • Gender comparisons in long term responses among patients receiving nelfinavir and dual
    nucleoside reverse transcriptase inhibitors as first ever highly active antiretroviral therapy
    F Palella, J Gathe, A Brutus, et al
     Abstract
41st ICAAC
 
  • Ravuconazole Does Not Affect the Pharmacokinetics of Nelfinavir
    Abstract
  • Correlation of Efficacy, Nelfinavir Pharmacokinetics and Diarrhea in Treatment-Naïve HIV Positive
    Patients Receiving Nelfinavir,  Zidovudine and Lamivudine
    Abstract
  • Efficacy of a Nelfinavir (NFV) and Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Based
    Salvage Regimen in Heavily     Pre-Treated Patients  
     Abstract
  • The Use of Nelfinavir and Two Nucleosides Concomitantly with Methadone Is Effective and Well-
    Tolerated in HepC Co-Infected Patients
    Abstract
  • Safety and Pharmacokinetics of Stavudine and Didanosine when  Co-Administered with Nelfinavir
     in HIV-Exposed Neonates
    Abstract
  • Effect of Methadone or LAAM on the Pharmacokinetics of Nelfinavir & M8
    Abstract  
  • The Pharmacokinetics of Combination Therapy with Nelfinavir (NFV) \ Plus Nevirapine (NVP) in
    HIV Positive Patients
    Abstract
3rd International Workshop on Clinical Pharmacology
of HIV Therapy

Nelfinavir Main Page Conferences Main Page Home Page

Archived Nelfinavir Conference Data